{"gene":"CD160","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":1998,"finding":"CD160 (BY55) was cloned and identified as a cysteine-rich, glycosylphosphatidylinositol (GPI)-anchored protein of 181 amino acids with a single Ig-like domain weakly homologous to killer inhibitory receptors; it forms tightly disulfide-linked multimers (~80 kDa unreduced, ~27 kDa reduced/carboxyamidomethylated) and is expressed on CD56dim CD16+ NK cells with high cytolytic activity but not on CD56bright CD16- NK cells.","method":"cDNA cloning, RNA blot analysis, immunoprecipitation with reduction and carboxyamidomethylation, flow cytometry","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — original molecular cloning with biochemical characterization of multimer structure and isoform-specific expression","pmids":["9743336"],"is_preprint":false},{"year":2002,"finding":"CD160 (BY55) acts as a co-receptor in TCR signal transduction: engagement of CD160 on CD28-negative CD8+ effector T cells enhances CD3-induced proliferation, and CD160 co-precipitates with the protein tyrosine kinase p56lck and tyrosine-phosphorylated zeta chains upon TCR-CD3 activation.","method":"Anti-CD160 mAb stimulation of primary T cells, proliferation assays, co-immunoprecipitation","journal":"International immunology","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP of signaling molecules with functional proliferation readout, single lab","pmids":["11978774"],"is_preprint":false},{"year":2002,"finding":"CD160 expressed on circulating CD56dim NK cells mediates cytotoxic activity against K562 target cells via engagement of HLA-C molecules; direct interaction between recombinant soluble HLA-Cw3 and CD160 proteins was demonstrated, and CD158b inhibitory receptors partially interfered with CD160-mediated cytotoxicity.","method":"Functional cytotoxicity assays with anti-CD160 mAb blocking, binding assay with recombinant soluble proteins, flow cytometry","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — direct protein interaction demonstrated with recombinant proteins plus functional cytotoxicity assay; moderate evidence","pmids":["12486241"],"is_preprint":false},{"year":2007,"finding":"CD160-mediated NK cell effector functions (cytotoxicity and cytokine production including IFN-γ, TNF-α, and IL-6) require phosphatidylinositol 3-kinase (PI3K) recruitment: CD160 engagement induces polarization and co-localization with PI3K, phosphorylation of Akt, activation of the ERK downstream pathway, and involvement of upstream Syk kinase.","method":"Confocal microscopy, pharmacological PI3K/MEK/Syk inhibitors, western blotting for phospho-Akt/phospho-ERK/phospho-Syk, cytotoxicity and cytokine release assays","journal":"International immunology","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (imaging, pharmacological inhibitors, western blot) in single lab establishing signaling cascade","pmids":["17307798"],"is_preprint":false},{"year":2009,"finding":"CD160 was identified as a ligand for HVEM (herpesvirus entry mediator) that delivers a coinhibitory signal; the cysteine-rich domain 1 (CRD1) of HVEM is essential for binding of CD160 (and BTLA) but not the costimulatory ligand LIGHT, and deletion or blockade of HVEM CRD1 abolishes CD160/BTLA binding and converts HVEM to a dominant costimulatory molecule.","method":"Binding assays, domain deletion/blockade experiments, functional T cell activation assays","journal":"Immunological reviews","confidence":"Medium","confidence_rationale":"Tier 2 — domain-mapping with functional readout; review summarizing experimental data from primary studies","pmids":["19426226"],"is_preprint":false},{"year":2010,"finding":"In CLL B cells (which aberrantly express CD160), CD160 signaling promotes survival by upregulating Bcl-2, Bcl-xL, and Mcl-1, reduces mitochondrial membrane potential collapse and cytochrome c release, induces DNA synthesis and proliferation, stimulates IL-6 and IL-8 secretion, and these effects are dose-dependently suppressed by PI3K inhibitors.","method":"CD160 stimulation of primary CLL cells, cell viability assays, western blotting for Bcl-2 family proteins, mitochondrial potential assays, cytochrome c release, BrdU proliferation, ELISA, PI3K inhibitor pharmacology","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods demonstrating PI3K-dependent survival signaling with mechanistic endpoints","pmids":["20164468"],"is_preprint":false},{"year":2011,"finding":"CD160 is expressed on endothelial cells of newly formed blood vessels in human colon carcinoma and mouse melanoma but not in healthy tissue vessels; a monoclonal antibody (CL1-R2) targeting CD160 exerted antiangiogenic effects in multiple animal models (rabbit cornea FGF2-induced neovascularization, mouse oxygen-induced retinopathy, mouse Matrigel plug), and combined with chemotherapy caused regression and normalization of tumor vasculature.","method":"Immunohistochemistry, rabbit cornea assay, mouse oxygen-induced retinopathy, Matrigel plug assay, Doppler ultrasonography, intravital microscopy, histology","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — multiple in vivo models with functional vascular readouts in a single study","pmids":["21482699"],"is_preprint":false},{"year":2011,"finding":"CD160 is a unique GPI-anchored activating NK receptor that signals through PI3K recruitment and lacks intrinsic ITAMs; it recognizes both MHC class Ia and Ib molecules and triggers cytotoxicity and proinflammatory cytokine production (IFN-γ, TNF-α, IL-6, IL-8, MIP1-β) at levels exceeding those induced by CD16 engagement.","method":"Functional NK cytotoxicity and cytokine release assays, specific antibody engagement, comparison with CD16-mediated responses","journal":"Immunology letters","confidence":"Medium","confidence_rationale":"Tier 2 — review synthesizing multiple experimental findings from primary studies; GPI-anchor/ITAM-lacking characterization is structurally grounded","pmids":["21324341"],"is_preprint":false},{"year":2012,"finding":"Blocking the CD160–HVEM interaction with anti-HVEM antibody increased HIV-specific CD8 T cell proliferation and cytokine production, demonstrating that CD160 signals through HVEM to suppress T cell function; co-expression of CD160 and PD-1 on CD8 T cells defines a highly exhausted subset with downregulated NFκB signaling and upregulated inhibitors of T cell survival.","method":"HVEM blockade functional assay, flow cytometry, transcriptional profiling (microarray)","journal":"PLoS pathogens","confidence":"Medium","confidence_rationale":"Tier 2 — ligand blockade functional rescue plus transcriptional mechanistic characterization; single lab","pmids":["22916009"],"is_preprint":false},{"year":2013,"finding":"HVEM specifically activates CD160 on human CD56dim NK cells: HVEM engagement costimulated NK cells via CD160 (not BTLA), enhanced IFN-γ and TNF-α secretion induced by type I IFN and IL-2, and caused rapid hyperphosphorylation of ERK1/2 and AKT and enhanced cytolysis of target cells. In contrast, HVEM activation of BTLA reduced cytolysis.","method":"Human NK cell stimulation assays, selective receptor engagement with HVEM ligand, phosphoprotein western blotting (ERK1/2, AKT), cytotoxicity assays, cytokine ELISA","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 — mechanistic signaling dissection (phosphoproteins) plus functional cytotoxicity and cytokine readouts; multiple orthogonal methods","pmids":["23761635"],"is_preprint":false},{"year":2014,"finding":"CD160 negatively regulates TCR-mediated signaling independently of PD-1: CD160+ CD8 T cells have reduced proliferation and perforin expression, and blockade of the CD160/CD160-ligand interaction restores proliferation in proportion to the ex vivo frequency of CD160+ cells. CD160 expression was not induced by T cell activation unlike PD-1.","method":"CD160 ligand blockade functional assay, flow cytometry, proliferation assays with virus-specific CD8 T cells (influenza, EBV, CMV antigens)","journal":"PLoS pathogens","confidence":"Medium","confidence_rationale":"Tier 2 — functional rescue by receptor blockade with multiple virus specificities; single lab","pmids":["25255144"],"is_preprint":false},{"year":2014,"finding":"CD160 exists in two isoforms (CD160-GPI and CD160-TM) both expressed in human primary CD4+ and CD8+ T cells; both isoforms bind HVEM, though CD160-TM binds less efficiently. HVEM antibodies blocked binding to CD160-GPI but paradoxically enhanced binding to CD160-TM, suggesting antibody-induced HVEM multimerization or conformational change. CD160-GPI triggering (via bead-bound HVEM-Fc or anti-CD160 mAb) enhanced Jurkat cell activation, consistent with a costimulatory role.","method":"Quantitative RT-PCR, flow cytometry, Time-Resolved Fluorescence binding assay, Jurkat cell activation assay","journal":"Journal of translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 — isoform identification and binding characterization with functional cell activation assay; single lab","pmids":["25179432"],"is_preprint":false},{"year":2007,"finding":"A novel CD160+CD4+ T cell subset was identified in inflammatory skin lesions (atopic dermatitis, contact dermatitis, psoriasis); CD160 engagement acted as a co-activator receptor for CD3-induced proliferation in this subset. CD160 transcripts could be induced in IL-2 or IL-15-activated CD4+ peripheral blood lymphocytes.","method":"Immunohistochemistry of skin biopsies, RT-PCR, T cell proliferation assay with anti-CD160 co-stimulation","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2-3 — identification of new CD4+ subset with functional co-stimulation assay; single lab","pmids":["17218942"],"is_preprint":false},{"year":2019,"finding":"Crystal structures of the human CD160 extracellular domain alone and in complex with HVEM were solved; CD160 adopts a unique variation of the immunoglobulin fold, exists as a monomer in solution, and the CD160:HVEM assembly exhibits 1:1 stoichiometry with a binding interface similar to that of the BTLA:HVEM complex.","method":"X-ray crystallography, solution biophysics","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 — crystal structure of CD160 alone and CD160:HVEM complex with 1:1 stoichiometry determination","pmids":["31230945"],"is_preprint":false},{"year":2021,"finding":"Crystal structures of HVEM-LIGHT-CD160 ternary complex demonstrated that HVEM can interact simultaneously with LIGHT (TNF ligand) and CD160 (Ig superfamily member) via distinct non-overlapping surfaces; HVEM mutants selectively recognizing either TNF or Ig ligands showed that LIGHT mediates bacterial clearance in the intestine while Ig ligands (including CD160) ameliorate liver inflammation in vivo.","method":"X-ray crystallography (ternary complex), site-directed mutagenesis, knockin mouse models with selective HVEM mutants","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — ternary complex crystal structure plus genetic knockin mice dissecting ligand-specific functions in vivo","pmids":["34709351"],"is_preprint":false},{"year":2018,"finding":"CD160 provides costimulatory signals to CD8+ T cells required for optimal clearance of oral Listeria monocytogenes infection: CD160-/- mice failed to clear infection efficiently, with reduced frequencies of granzyme B+ intraepithelial lymphocytes and granzyme B+, IFN-γ+TNF-α+ splenic CD8+ T cells. Adoptive transfer of CD160-/- CD8+ T cells into RAG-/- recipients caused higher mortality and bacterial burden than WT CD8+ T cells. NK cells did not contribute to impaired clearance.","method":"CD160 knockout mice, oral infection model, flow cytometry, adoptive transfer experiments, RAG-/- recipients","journal":"ImmunoHorizons","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with adoptive transfer epistasis; multiple orthogonal readouts","pmids":["31022694"],"is_preprint":false},{"year":2018,"finding":"Reduced CD160 expression on intratumoral NK cells in HCC impairs IFN-γ production; TGFβ1 in the tumor microenvironment interferes with IFN-γ production by CD160+ NK cells, and TGFβ1 blockade specifically restores IFN-γ production by CD160+ NK cells. Transcriptomic analysis of sorted CD160+ vs CD160- NK cells confirmed functional activation signatures in CD160+ cells.","method":"Flow cytometry, transcriptomic microarray/gene set enrichment analysis of sorted NK cell subsets, TGFβ1 blockade functional assay, histology of patient tumors","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic TGFβ1 blockade experiment plus transcriptomics; single study with multiple orthogonal methods","pmids":["30232222"],"is_preprint":false},{"year":2021,"finding":"In patients with CLL, IL-16 in the plasma (highly elevated) directly upregulates CD160 expression on T cells, and extracellular vesicles (EVs) from CLL plasma serve as an additional source of CD160 that can be taken up by T cells, contributing to CD160-associated T cell exhaustion.","method":"Plasma cytokine profiling, EV characterization, in vitro IL-16 treatment of T cells, flow cytometry","journal":"Journal for immunotherapy of cancer","confidence":"Medium","confidence_rationale":"Tier 2-3 — in vitro upregulation experiment plus EV uptake; single lab study","pmids":["33931471"],"is_preprint":false},{"year":1994,"finding":"The BY55 (CD160) antigen (~80 kDa on the cell surface) marks cytotoxic lymphocytes; within cord blood, BY55+ cells correspond exclusively to a CD3- subset that contains the entire natural killer activity, demonstrating that CD160 expression is restricted to cytotoxic NK and T cell lineages.","method":"BY55 monoclonal antibody staining, flow cytometry, functional NK cytotoxicity assays on cord blood and bone marrow lymphocytes","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 — functional NK activity directly linked to BY55+ subset by flow cytometry and cytotoxicity assays","pmids":["8090781"],"is_preprint":false},{"year":2006,"finding":"Murine CD160 is expressed predominantly on CD44high CD8+ memory T cells (both effector memory and central memory) and recently activated CD8+ T cells; CD160+ CD8+ T cells from OT-1 transgenic mice produce IFN-γ more rapidly than CD160- CD8+ T cells upon antigen stimulation, and soluble CD160 is released after in vitro CD3-mediated stimulation.","method":"Anti-murine CD160 mAb generation, flow cytometry, in vitro stimulation assays, intracellular IFN-γ staining","journal":"Immunology letters","confidence":"Medium","confidence_rationale":"Tier 2 — first characterization of murine CD160 with functional antigen-specific T cell readout","pmids":["16764942"],"is_preprint":false}],"current_model":"CD160 is a GPI-anchored (with an alternative transmembrane isoform) single-domain Ig superfamily receptor that, upon engagement of HLA class I molecules or HVEM (its principal signaling partner, revealed by 1:1 crystal structure), activates NK cells and CD8+ T cells via a PI3K→Akt/ERK signaling cascade (with upstream Syk involvement) to drive cytotoxicity and proinflammatory cytokine production (IFN-γ, TNF-α, IL-6, IL-8), while simultaneously delivering coinhibitory signals to exhausted CD8+ T cells that suppress TCR-driven proliferation; its function is context-dependent—costimulatory for NK cells and mucosal CD8+ T cells during infection, yet coinhibitory in chronic antigen settings—and is also expressed on tumor-associated endothelium where it supports pathological angiogenesis."},"narrative":{"teleology":[{"year":1994,"claim":"Establishing that CD160 (BY55) marks a cytotoxic lymphocyte lineage answered the basic question of which cells express this antigen, showing it defines the entire NK compartment in cord blood.","evidence":"Monoclonal antibody staining and functional NK cytotoxicity assays on cord blood and bone marrow lymphocytes","pmids":["8090781"],"confidence":"Medium","gaps":["No molecular identity or gene structure yet determined","Expression on T cell subsets not fully mapped"]},{"year":1998,"claim":"Molecular cloning of CD160 established its identity as a GPI-anchored, disulfide-linked multimeric Ig-superfamily receptor preferentially expressed on CD56dim CD16+ NK cells, providing the molecular framework for all subsequent functional studies.","evidence":"cDNA cloning, RNA blot analysis, immunoprecipitation under reducing/non-reducing conditions, flow cytometry","pmids":["9743336"],"confidence":"High","gaps":["Ligand identity unknown","Signaling mechanism undefined","Function beyond expression pattern not demonstrated"]},{"year":2002,"claim":"Two contemporaneous studies revealed CD160's dual functionality: it directly binds HLA-C to trigger NK cytotoxicity and acts as a TCR co-receptor on CD28-negative CD8+ T cells by co-precipitating with p56lck and phospho-ζ chains, establishing CD160 as an activating receptor on both NK cells and T cells.","evidence":"Recombinant soluble protein binding assays, functional cytotoxicity assays, co-immunoprecipitation, T cell proliferation assays","pmids":["12486241","11978774"],"confidence":"High","gaps":["Signaling intermediates downstream of lck/ζ not mapped","p56lck co-IP not validated reciprocally","Whether CD160 inhibitory function exists not yet addressed"]},{"year":2007,"claim":"Mapping the CD160 signaling cascade in NK cells resolved how a GPI-anchored receptor lacking ITAMs transduces activation signals: PI3K recruitment leads to Akt and ERK phosphorylation with upstream Syk kinase involvement, driving both cytotoxicity and cytokine secretion. Concurrently, CD160 was identified as a co-activator on a novel CD4+ T cell subset in inflammatory skin.","evidence":"Confocal microscopy, pharmacological PI3K/MEK/Syk inhibitors, western blotting, cytotoxicity and cytokine assays; immunohistochemistry of skin biopsies and T cell proliferation assays","pmids":["17307798","17218942"],"confidence":"High","gaps":["Adaptor protein linking GPI-anchored CD160 to intracellular Syk/PI3K unknown","Role of lipid raft partitioning not formally tested"]},{"year":2009,"claim":"Identification of HVEM as a CD160 ligand and mapping the interaction to HVEM CRD1 reframed CD160 as part of a bidirectional HVEM signaling network, where CRD1 engagement by CD160/BTLA delivers coinhibitory signals while LIGHT engages distinct CRDs for costimulation.","evidence":"Binding assays, HVEM domain deletion/blockade, functional T cell activation assays","pmids":["19426226"],"confidence":"Medium","gaps":["Review-level summary; primary structural data for the CD160:HVEM interface not yet available","Whether CD160 and BTLA compete for HVEM CRD1 or cooperate not resolved"]},{"year":2010,"claim":"Demonstration that CD160 signals in CLL B cells to upregulate Bcl-2/Bcl-xL/Mcl-1 via PI3K, promoting survival and cytokine secretion, expanded CD160's role beyond lymphocyte activation to a pro-survival pathway exploited in malignancy.","evidence":"CLL primary cell stimulation, viability and BrdU assays, western blotting for Bcl-2 family, mitochondrial potential assays, PI3K inhibitor pharmacology","pmids":["20164468"],"confidence":"High","gaps":["Whether this represents aberrant expression or a normal B cell function is unclear","Ligand triggering CD160 on CLL cells in vivo not identified"]},{"year":2011,"claim":"Discovery of CD160 expression on tumor-associated endothelium and demonstration that anti-CD160 antibody CL1-R2 blocks pathological angiogenesis in multiple in vivo models revealed a non-immune function for CD160 in vascular biology.","evidence":"Immunohistochemistry, rabbit cornea neovascularization, mouse oxygen-induced retinopathy, Matrigel plug assay, Doppler ultrasonography","pmids":["21482699"],"confidence":"High","gaps":["Endothelial CD160 signaling pathway not dissected","Ligand for CD160 on endothelial cells not identified","Whether angiogenic role is HVEM-dependent unknown"]},{"year":2012,"claim":"Blocking the CD160–HVEM axis on HIV-specific CD8+ T cells restored proliferation and cytokine production, directly demonstrating that CD160-HVEM engagement delivers a coinhibitory signal in chronic infection and that CD160+PD-1+ double-positive cells represent the most exhausted subset with downregulated NF-κB.","evidence":"Anti-HVEM antibody blockade, flow cytometry, microarray transcriptional profiling of HIV-specific CD8+ T cells","pmids":["22916009"],"confidence":"Medium","gaps":["Blockade targeted HVEM, not CD160 directly, so contributions of BTLA cannot be fully excluded","NF-κB downregulation is correlative from transcriptomics"]},{"year":2013,"claim":"Selective engagement experiments on human NK cells resolved the paradox of HVEM's dual signaling: HVEM activates CD160 (not BTLA) on CD56dim NK cells to costimulate IFN-γ/TNF-α and hyperphosphorylate ERK1/2 and AKT, while BTLA engagement is inhibitory—demonstrating that the same ligand elicits opposite outcomes through different receptors.","evidence":"Human NK cell stimulation with selective HVEM engagement, phosphoprotein western blotting, cytotoxicity and cytokine ELISA","pmids":["23761635"],"confidence":"High","gaps":["How cell-type context determines whether CD160 or BTLA dominates the response is unknown"]},{"year":2014,"claim":"Two advances clarified CD160's inhibitory T cell role and isoform biology: CD160 was shown to inhibit TCR signaling independently of PD-1 (blockade of CD160-ligand interaction restored proliferation proportional to CD160+ frequency), and a transmembrane isoform (CD160-TM) was identified that binds HVEM less efficiently than CD160-GPI, with HVEM antibodies paradoxically enhancing CD160-TM binding.","evidence":"CD160 ligand blockade in virus-specific CD8+ T cells; quantitative RT-PCR, time-resolved fluorescence binding, Jurkat activation assays","pmids":["25255144","25179432"],"confidence":"Medium","gaps":["CD160-TM signaling pathway not dissected","Whether GPI and TM isoforms deliver opposing signals in the same cell unknown","Functional significance of antibody-enhanced CD160-TM binding unresolved"]},{"year":2018,"claim":"In vivo genetic evidence from CD160-knockout mice demonstrated that CD160 is required for optimal CD8+ T cell effector function during mucosal Listeria infection, with adoptive transfer confirming a cell-intrinsic costimulatory role; separately, TGF-β1 in the HCC tumor microenvironment was shown to suppress IFN-γ production by CD160+ NK cells.","evidence":"CD160−/− mice with oral Listeria infection, adoptive transfer into RAG−/− recipients; flow cytometry and TGF-β1 blockade in HCC patient NK cells with transcriptomic validation","pmids":["31022694","30232222"],"confidence":"High","gaps":["Whether CD160 costimulation in vivo is HVEM-dependent or MHC-dependent not determined","Mechanism by which TGF-β1 suppresses CD160+ NK cell function not elucidated"]},{"year":2019,"claim":"Crystal structures of CD160 alone and in complex with HVEM established 1:1 stoichiometry and revealed a unique Ig fold variant, providing the atomic basis for the CD160-HVEM interaction and showing it overlaps the BTLA-binding interface on HVEM.","evidence":"X-ray crystallography, solution biophysics","pmids":["31230945"],"confidence":"High","gaps":["No structure of CD160 bound to MHC class I","GPI-anchor and membrane-proximal region not resolved"]},{"year":2021,"claim":"The ternary HVEM-LIGHT-CD160 crystal structure demonstrated that HVEM simultaneously engages a TNF ligand and an Ig-domain receptor via non-overlapping surfaces, and genetic knockin mice showed these two binding modes partition distinct immunological functions (bacterial clearance vs. liver inflammation control) in vivo. Separately, IL-16 and CLL-derived extracellular vesicles were shown to upregulate CD160 on T cells, linking the tumor microenvironment to CD160-mediated exhaustion.","evidence":"X-ray crystallography of ternary complex, HVEM mutant knockin mice; CLL plasma cytokine profiling, EV characterization, in vitro IL-16 treatment","pmids":["34709351","33931471"],"confidence":"High","gaps":["How ternary complex formation affects downstream signaling output quantitatively is unknown","Whether EV-transferred CD160 is functional on recipient T cells not formally demonstrated"]},{"year":null,"claim":"The molecular mechanism by which a GPI-anchored receptor (lacking intracellular domains) activates Syk and PI3K remains unresolved—the putative transmembrane adaptor or lipid-raft partner that couples CD160-GPI to intracellular kinases has not been identified.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No adaptor protein linking GPI-anchored CD160 to cytoplasmic signaling identified","Relative physiological contributions of CD160-GPI vs CD160-TM isoforms undefined","Structural basis of CD160 recognition of MHC class I molecules unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[2,4,9,13]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[8,10,15]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,11,18]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,3,8,9,10,15]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,5,9]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[5]}],"complexes":[],"partners":["TNFRSF14","TNFSF14","BTLA"],"other_free_text":[]},"mechanistic_narrative":"CD160 is a GPI-anchored, single Ig-domain receptor on cytotoxic lymphocytes and endothelial cells that delivers context-dependent activating or inhibitory signals through engagement of MHC class I molecules and HVEM. On NK cells and effector CD8+ T cells, CD160 ligation triggers a PI3K→Akt/ERK signaling cascade (with upstream Syk involvement) that drives cytotoxicity and proinflammatory cytokine production (IFN-γ, TNF-α, IL-6, IL-8), and CD160-deficient mice fail to clear mucosal Listeria infection due to impaired CD8+ T cell effector function [PMID:17307798, PMID:23761635, PMID:31022694]. Conversely, CD160 engagement via HVEM on chronically stimulated CD8+ T cells delivers a coinhibitory signal that suppresses TCR-driven proliferation independently of PD-1, defining CD160+PD-1+ cells as a deeply exhausted subset [PMID:22916009, PMID:25255144]. Structurally, CD160 binds HVEM CRD1 with 1:1 stoichiometry at a site overlapping the BTLA-binding surface but non-overlapping with LIGHT, and HVEM can simultaneously engage LIGHT and CD160 in a ternary complex that partitions distinct immunoregulatory outputs in vivo [PMID:31230945, PMID:34709351]."},"prefetch_data":{"uniprot":{"accession":"O95971","full_name":"CD160 antigen","aliases":["Natural killer cell receptor BY55"],"length_aa":181,"mass_kda":19.8,"function":"Receptor on immune cells capable to deliver stimulatory or inhibitory signals that regulate cell activation and differentiation. Exists as a GPI-anchored and as a transmembrane form, each likely initiating distinct signaling pathways via phosphoinositol 3-kinase in activated NK cells and via LCK and CD247/CD3 zeta chain in activated T cells (PubMed:11978774, PubMed:17307798, PubMed:19109136). Receptor for both classical and non-classical MHC class I molecules (PubMed:12486241, PubMed:9973372). In the context of acute viral infection, recognizes HLA-C and triggers NK cell cytotoxic activity, likely playing a role in anti-viral innate immune response (PubMed:12486241). On CD8+ T cells, binds HLA-A2-B2M in complex with a viral peptide and provides a costimulatory signal to activated/memory T cells (PubMed:9973372). Upon persistent antigen stimulation, such as occurs during chronic viral infection, may progressively inhibit TCR signaling in memory CD8+ T cells, contributing to T cell exhaustion (PubMed:25255144). On endothelial cells, recognizes HLA-G and controls angiogenesis in immune privileged sites (PubMed:16809620). Receptor or ligand for TNF superfamily member TNFRSF14, participating in bidirectional cell-cell contact signaling between antigen presenting cells and lymphocytes. Upon ligation of TNFRSF14, provides stimulatory signal to NK cells enhancing IFNG production and anti-tumor immune response (By similarity). On activated CD4+ T cells, interacts with TNFRSF14 and down-regulates CD28 costimulatory signaling, restricting memory and alloantigen-specific immune response (PubMed:18193050). In the context of bacterial infection, acts as a ligand for TNFRSF14 on epithelial cells, triggering the production of antimicrobial proteins and pro-inflammatory cytokines (By similarity) The soluble GPI-cleaved form, usually released by activated lymphocytes, might play an immune regulatory role by limiting lymphocyte effector functions","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/O95971/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CD160","classification":"Not Classified","n_dependent_lines":6,"n_total_lines":1208,"dependency_fraction":0.004966887417218543},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CD160","total_profiled":1310},"omim":[{"mim_id":"604463","title":"CD160 ANTIGEN; CD160","url":"https://www.omim.org/entry/604463"},{"mim_id":"602746","title":"TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 14; TNFRSF14","url":"https://www.omim.org/entry/602746"},{"mim_id":"102582","title":"SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3; STAT3","url":"https://www.omim.org/entry/102582"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"bone marrow","ntpm":4.8},{"tissue":"brain","ntpm":15.2},{"tissue":"intestine","ntpm":4.4},{"tissue":"liver","ntpm":4.7},{"tissue":"lymphoid tissue","ntpm":12.7}],"url":"https://www.proteinatlas.org/search/CD160"},"hgnc":{"alias_symbol":["BY55","NK1","NK28"],"prev_symbol":[]},"alphafold":{"accession":"O95971","domains":[{"cath_id":"2.60.40.10","chopping":"27-140","consensus_level":"high","plddt":90.5021,"start":27,"end":140}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O95971","model_url":"https://alphafold.ebi.ac.uk/files/AF-O95971-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O95971-F1-predicted_aligned_error_v6.png","plddt_mean":75.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CD160","jax_strain_url":"https://www.jax.org/strain/search?query=CD160"},"sequence":{"accession":"O95971","fasta_url":"https://rest.uniprot.org/uniprotkb/O95971.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O95971/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O95971"}},"corpus_meta":[{"pmid":"9143699","id":"PMC_9143699","title":"Mouse CD1-specific NK1 T cells: development, specificity, and function.","date":"1997","source":"Annual review of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9143699","citation_count":986,"is_preprint":false},{"pmid":"11927628","id":"PMC_11927628","title":"A natural killer T (NKT) cell developmental pathway iInvolving a thymus-dependent NK1.1(-)CD4(+) CD1d-dependent precursor stage.","date":"2002","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11927628","citation_count":282,"is_preprint":false},{"pmid":"9571643","id":"PMC_9571643","title":"The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles.","date":"1998","source":"Neuropeptides","url":"https://pubmed.ncbi.nlm.nih.gov/9571643","citation_count":248,"is_preprint":false},{"pmid":"19426226","id":"PMC_19426226","title":"The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.","date":"2009","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19426226","citation_count":247,"is_preprint":false},{"pmid":"19830744","id":"PMC_19830744","title":"CCR6 and NK1.1 distinguish between IL-17A and IFN-gamma-producing gammadelta effector T cells.","date":"2009","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19830744","citation_count":232,"is_preprint":false},{"pmid":"10190898","id":"PMC_10190898","title":"Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease.","date":"1999","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10190898","citation_count":232,"is_preprint":false},{"pmid":"10671176","id":"PMC_10671176","title":"Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists.","date":"1999","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/10671176","citation_count":222,"is_preprint":false},{"pmid":"9834059","id":"PMC_9834059","title":"Differentiation of human NK cells into NK1 and NK2 subsets.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9834059","citation_count":222,"is_preprint":false},{"pmid":"12562137","id":"PMC_12562137","title":"Neurobiology of substance P and the NK1 receptor.","date":"2002","source":"The Journal of clinical psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/12562137","citation_count":219,"is_preprint":false},{"pmid":"14666114","id":"PMC_14666114","title":"Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression.","date":"2004","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/14666114","citation_count":216,"is_preprint":false},{"pmid":"10443564","id":"PMC_10443564","title":"The tachykinin NK1 receptor in the brain: pharmacology and putative functions.","date":"1999","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10443564","citation_count":176,"is_preprint":false},{"pmid":"9574822","id":"PMC_9574822","title":"The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation.","date":"1997","source":"Neuropeptides","url":"https://pubmed.ncbi.nlm.nih.gov/9574822","citation_count":173,"is_preprint":false},{"pmid":"26421291","id":"PMC_26421291","title":"Biological and Pharmacological Aspects of the NK1-Receptor.","date":"2015","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/26421291","citation_count":161,"is_preprint":false},{"pmid":"24705689","id":"PMC_24705689","title":"Involvement of substance P and the NK-1 receptor in human pathology.","date":"2014","source":"Amino acids","url":"https://pubmed.ncbi.nlm.nih.gov/24705689","citation_count":157,"is_preprint":false},{"pmid":"20007250","id":"PMC_20007250","title":"HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation.","date":"2009","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/20007250","citation_count":133,"is_preprint":false},{"pmid":"17923504","id":"PMC_17923504","title":"Development and function of murine B220+CD11c+NK1.1+ cells identify them as a subset of NK cells.","date":"2007","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17923504","citation_count":130,"is_preprint":false},{"pmid":"22916009","id":"PMC_22916009","title":"CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction.","date":"2012","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/22916009","citation_count":123,"is_preprint":false},{"pmid":"8636243","id":"PMC_8636243","title":"Heparin induces dimerization and confers proliferative activity onto the hepatocyte growth factor antagonists NK1 and NK2.","date":"1996","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/8636243","citation_count":123,"is_preprint":false},{"pmid":"23933301","id":"PMC_23933301","title":"Involvement of substance P and the NK-1 receptor in cancer progression.","date":"2013","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/23933301","citation_count":118,"is_preprint":false},{"pmid":"9743336","id":"PMC_9743336","title":"Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9743336","citation_count":114,"is_preprint":false},{"pmid":"12562139","id":"PMC_12562139","title":"Imaging substance P receptors (NK1) in the living human brain using positron emission tomography.","date":"2002","source":"The Journal of clinical psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/12562139","citation_count":113,"is_preprint":false},{"pmid":"16751398","id":"PMC_16751398","title":"Molecular and genetic basis for strain-dependent NK1.1 alloreactivity of mouse NK cells.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16751398","citation_count":110,"is_preprint":false},{"pmid":"12486241","id":"PMC_12486241","title":"Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12486241","citation_count":108,"is_preprint":false},{"pmid":"12620925","id":"PMC_12620925","title":"Substance P via NK1 receptor facilitates hyperactive bladder afferent signaling via action of ROS.","date":"2003","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12620925","citation_count":87,"is_preprint":false},{"pmid":"16547241","id":"PMC_16547241","title":"Long-term retention of mature NK1.1+ NKT cells in the thymus.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16547241","citation_count":86,"is_preprint":false},{"pmid":"9164926","id":"PMC_9164926","title":"NK1.1+ CD4+ T cells lose NK1.1 expression upon in vitro activation.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9164926","citation_count":77,"is_preprint":false},{"pmid":"23761635","id":"PMC_23761635","title":"CD160 activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23761635","citation_count":74,"is_preprint":false},{"pmid":"21226668","id":"PMC_21226668","title":"The NK-1 receptor: a new target in cancer therapy.","date":"2011","source":"Current drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/21226668","citation_count":73,"is_preprint":false},{"pmid":"11805341","id":"PMC_11805341","title":"The NK1 receptor mediates both the hyperalgesia and the resistance to morphine in mice lacking noradrenaline.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11805341","citation_count":71,"is_preprint":false},{"pmid":"16127708","id":"PMC_16127708","title":"Species differences in tachykinin receptor distribution: further evidence that the substance P (NK1) receptor predominates in human brain.","date":"2005","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/16127708","citation_count":67,"is_preprint":false},{"pmid":"21324341","id":"PMC_21324341","title":"CD160: a unique activating NK cell receptor.","date":"2011","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/21324341","citation_count":66,"is_preprint":false},{"pmid":"25255144","id":"PMC_25255144","title":"CD160-associated CD8 T-cell functional impairment is independent of PD-1 expression.","date":"2014","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/25255144","citation_count":66,"is_preprint":false},{"pmid":"10861049","id":"PMC_10861049","title":"CD1d-specific NK1.1+ T cells with a transgenic variant TCR.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10861049","citation_count":65,"is_preprint":false},{"pmid":"11179779","id":"PMC_11179779","title":"Localization of NK1 and NK3 receptors in guinea-pig brain.","date":"2001","source":"Regulatory peptides","url":"https://pubmed.ncbi.nlm.nih.gov/11179779","citation_count":60,"is_preprint":false},{"pmid":"14640927","id":"PMC_14640927","title":"Aprepitant--a novel NK1-receptor antagonist.","date":"2003","source":"Expert opinion on pharmacotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/14640927","citation_count":56,"is_preprint":false},{"pmid":"11978774","id":"PMC_11978774","title":"BY55/CD160 acts as a co-receptor in TCR signal transduction of a human circulating cytotoxic effector T lymphocyte subset lacking CD28 expression.","date":"2002","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11978774","citation_count":55,"is_preprint":false},{"pmid":"11157089","id":"PMC_11157089","title":"The NK1 receptor is essential for the full expression of noxious inhibitory controls in the mouse.","date":"2001","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/11157089","citation_count":53,"is_preprint":false},{"pmid":"10954033","id":"PMC_10954033","title":"The role of tachykinins via NK1 receptors in progression of human gliomas.","date":"2000","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/10954033","citation_count":51,"is_preprint":false},{"pmid":"12562140","id":"PMC_12562140","title":"Clinical experience with substance P receptor (NK1) antagonists in depression.","date":"2002","source":"The Journal of clinical psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/12562140","citation_count":50,"is_preprint":false},{"pmid":"16155744","id":"PMC_16155744","title":"Visualization and quantification of neurokinin-1 (NK1) receptors in the human brain.","date":"2005","source":"Molecular imaging and biology","url":"https://pubmed.ncbi.nlm.nih.gov/16155744","citation_count":48,"is_preprint":false},{"pmid":"2143439","id":"PMC_2143439","title":"In vitro and in vivo analysis of bone marrow-derived CD3+, CD4-, CD8-, NK1.1+ cell lines.","date":"1990","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/2143439","citation_count":48,"is_preprint":false},{"pmid":"8090781","id":"PMC_8090781","title":"BY55 monoclonal antibody delineates within human cord blood and bone marrow lymphocytes distinct cell subsets mediating cytotoxic activity.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8090781","citation_count":48,"is_preprint":false},{"pmid":"12562138","id":"PMC_12562138","title":"Behavioral and physiologic effects of genetic or pharmacologic inactivation of the substance P receptor (NK1).","date":"2002","source":"The Journal of clinical psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/12562138","citation_count":48,"is_preprint":false},{"pmid":"8717372","id":"PMC_8717372","title":"Expression of tachykinin NK1 receptor mRNA in dorsal root ganglia of the mouse.","date":"1996","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/8717372","citation_count":47,"is_preprint":false},{"pmid":"30232222","id":"PMC_30232222","title":"Reduced CD160 Expression Contributes to Impaired NK-cell Function and Poor Clinical Outcomes in Patients with HCC.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30232222","citation_count":47,"is_preprint":false},{"pmid":"10650452","id":"PMC_10650452","title":"Substance P (NK1) receptors in the cingulate cortex in unipolar and bipolar mood disorder and schizophrenia.","date":"2000","source":"Biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/10650452","citation_count":47,"is_preprint":false},{"pmid":"12492418","id":"PMC_12492418","title":"The murine neurokinin NK1 receptor gene contributes to the adult hypoxic facilitation of ventilation.","date":"2002","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/12492418","citation_count":46,"is_preprint":false},{"pmid":"12056558","id":"PMC_12056558","title":"New insights into the antidepressant actions of substance P (NK1 receptor) antagonists.","date":"2002","source":"Canadian journal of physiology and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12056558","citation_count":44,"is_preprint":false},{"pmid":"20164468","id":"PMC_20164468","title":"CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20164468","citation_count":42,"is_preprint":false},{"pmid":"12020057","id":"PMC_12020057","title":"Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists.","date":"2002","source":"Current opinion in investigational drugs (London, England : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/12020057","citation_count":42,"is_preprint":false},{"pmid":"19748515","id":"PMC_19748515","title":"Behavioural and neurochemical abnormalities in mice lacking functional tachykinin-1 (NK1) receptors: a model of attention deficit hyperactivity disorder.","date":"2009","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19748515","citation_count":42,"is_preprint":false},{"pmid":"25861784","id":"PMC_25861784","title":"NK-1 Antagonists and Itch.","date":"2015","source":"Handbook of experimental pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25861784","citation_count":41,"is_preprint":false},{"pmid":"33931471","id":"PMC_33931471","title":"Expanded antigen-experienced CD160+CD8+effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia.","date":"2021","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33931471","citation_count":40,"is_preprint":false},{"pmid":"24605029","id":"PMC_24605029","title":"Involvement of substance P and the NK-1 receptor in pancreatic cancer.","date":"2014","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/24605029","citation_count":40,"is_preprint":false},{"pmid":"16764942","id":"PMC_16764942","title":"Characterization of murine CD160+ CD8+ T lymphocytes.","date":"2006","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/16764942","citation_count":40,"is_preprint":false},{"pmid":"25284210","id":"PMC_25284210","title":"NK1.1+ CD8+ T cells escape TGF-β control and contribute to early microbial pathogen response.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25284210","citation_count":39,"is_preprint":false},{"pmid":"23303056","id":"PMC_23303056","title":"The NK1 receptor antagonist L822429 reduces heroin reinforcement.","date":"2012","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23303056","citation_count":39,"is_preprint":false},{"pmid":"11985826","id":"PMC_11985826","title":"Stereospecific blockade of marble-burying behaviour in mice by selective, non-peptidergic neurokinin1 (NK1) receptor antagonists.","date":"2002","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11985826","citation_count":38,"is_preprint":false},{"pmid":"17895403","id":"PMC_17895403","title":"Peripheral tachykinins and the neurokinin receptor NK1 are required for platelet thrombus formation.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17895403","citation_count":37,"is_preprint":false},{"pmid":"24969614","id":"PMC_24969614","title":"Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells.","date":"2014","source":"Experimental brain research","url":"https://pubmed.ncbi.nlm.nih.gov/24969614","citation_count":36,"is_preprint":false},{"pmid":"21482699","id":"PMC_21482699","title":"A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor.","date":"2011","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21482699","citation_count":36,"is_preprint":false},{"pmid":"31230945","id":"PMC_31230945","title":"Structural Basis of CD160:HVEM Recognition.","date":"2019","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/31230945","citation_count":35,"is_preprint":false},{"pmid":"10754218","id":"PMC_10754218","title":"Localisation of tachykinin NK1 and NK3 receptors in the human prefrontal and visual cortex.","date":"2000","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/10754218","citation_count":35,"is_preprint":false},{"pmid":"7605934","id":"PMC_7605934","title":"Striatal neurones displaying substance P (NK1) receptor immunoreactivity in human and non-human primates.","date":"1995","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/7605934","citation_count":35,"is_preprint":false},{"pmid":"34347289","id":"PMC_34347289","title":"Granzyme A and CD160 expression delineates ILC1 with graded functions in the mouse liver.","date":"2021","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34347289","citation_count":34,"is_preprint":false},{"pmid":"2163859","id":"PMC_2163859","title":"The rabbit jugular vein is a contractile NK-1 receptor system.","date":"1990","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/2163859","citation_count":34,"is_preprint":false},{"pmid":"18954559","id":"PMC_18954559","title":"17beta-estradiol suppresses cytotoxicity and proliferative capacity of murine splenic NK1.1+ cells.","date":"2008","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18954559","citation_count":34,"is_preprint":false},{"pmid":"31190215","id":"PMC_31190215","title":"NK-1 Receptor Antagonists and Pruritus: Review of Current Literature.","date":"2019","source":"Dermatology and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31190215","citation_count":33,"is_preprint":false},{"pmid":"30538204","id":"PMC_30538204","title":"Crystal structure of the human NK1 tachykinin receptor.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/30538204","citation_count":32,"is_preprint":false},{"pmid":"31480582","id":"PMC_31480582","title":"The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy.","date":"2019","source":"Pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/31480582","citation_count":31,"is_preprint":false},{"pmid":"19369645","id":"PMC_19369645","title":"Murine endometrial and decidual NK1.1+ natural killer cells display a B220+CD11c+ cell surface phenotype.","date":"2009","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/19369645","citation_count":31,"is_preprint":false},{"pmid":"17307798","id":"PMC_17307798","title":"CD160-activating NK cell effector functions depend on the phosphatidylinositol 3-kinase recruitment.","date":"2007","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17307798","citation_count":30,"is_preprint":false},{"pmid":"15261332","id":"PMC_15261332","title":"Substance P (NK1) and somatostatin (sst2A) receptor immunoreactivity in NTS-projecting rat dorsal horn neurones activated by nociceptive afferent input.","date":"2004","source":"Journal of chemical neuroanatomy","url":"https://pubmed.ncbi.nlm.nih.gov/15261332","citation_count":30,"is_preprint":false},{"pmid":"11009081","id":"PMC_11009081","title":"Differential regulation of Ly49 expression on CD4+ and CD4-CD8- (double negative) NK1.1+ T cells.","date":"2000","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11009081","citation_count":30,"is_preprint":false},{"pmid":"31022694","id":"PMC_31022694","title":"CD160 Stimulates CD8+ T Cell Responses and Is Required for Optimal Protective Immunity to Listeria monocytogenes.","date":"2018","source":"ImmunoHorizons","url":"https://pubmed.ncbi.nlm.nih.gov/31022694","citation_count":29,"is_preprint":false},{"pmid":"11071316","id":"PMC_11071316","title":"Tachykinin NK1 and NK3 receptors in the prefrontal cortex of the human brain.","date":"2000","source":"Clinical and experimental pharmacology & physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11071316","citation_count":29,"is_preprint":false},{"pmid":"11864635","id":"PMC_11864635","title":"The human tachykinin NK1 (short form) and tachykinin NK4 receptor: a reappraisal.","date":"2002","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11864635","citation_count":28,"is_preprint":false},{"pmid":"12063723","id":"PMC_12063723","title":"[Why are substance P(NK1)-receptor antagonists ineffective in pain treatment?].","date":"2002","source":"Der Anaesthesist","url":"https://pubmed.ncbi.nlm.nih.gov/12063723","citation_count":28,"is_preprint":false},{"pmid":"11950514","id":"PMC_11950514","title":"Neurokinin NK1- and NK3-immunoreactive neurons in serotonergic cell groups in the rat brain.","date":"2002","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/11950514","citation_count":28,"is_preprint":false},{"pmid":"12687689","id":"PMC_12687689","title":"VR1-positive primary afferents contact NK1-positive spinoparabrachial neurons.","date":"2003","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/12687689","citation_count":28,"is_preprint":false},{"pmid":"16501582","id":"PMC_16501582","title":"[3H]GR205171 displays similar NK1 receptor binding profile in gerbil and human brain.","date":"2006","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16501582","citation_count":28,"is_preprint":false},{"pmid":"17218942","id":"PMC_17218942","title":"Identification of a novel CD160+ CD4+ T-lymphocyte subset in the skin: a possible role for CD160 in skin inflammation.","date":"2007","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/17218942","citation_count":28,"is_preprint":false},{"pmid":"10651631","id":"PMC_10651631","title":"Disulfide bridge engineering in the tachykinin NK1 receptor.","date":"2000","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10651631","citation_count":28,"is_preprint":false},{"pmid":"9122219","id":"PMC_9122219","title":"Generation of NK1.1+ T cell antigen receptor alpha/beta+ thymocytes associated with intact thymic structure.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9122219","citation_count":27,"is_preprint":false},{"pmid":"31862674","id":"PMC_31862674","title":"Carboplatin chemoresistance is associated with CD11b+/Ly6C+ myeloid release and upregulation of TIGIT and LAG3/CD160 exhausted T cells.","date":"2019","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31862674","citation_count":26,"is_preprint":false},{"pmid":"7692776","id":"PMC_7692776","title":"NK1 and NK2 receptors mediate tachykinin and resiniferatoxin-induced bronchospasm in guinea pigs.","date":"1993","source":"The American review of respiratory disease","url":"https://pubmed.ncbi.nlm.nih.gov/7692776","citation_count":26,"is_preprint":false},{"pmid":"17182540","id":"PMC_17182540","title":"Sensitivity of NK1.1-negative NKT cells to transgenic BATF defines a role for activator protein-1 in the expansion and maturation of immature NKT cells in the thymus.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17182540","citation_count":26,"is_preprint":false},{"pmid":"36793857","id":"PMC_36793857","title":"TCRαβ+NK1.1-CD4-CD8- double-negative T cells inhibit central and peripheral inflammation and ameliorate ischemic stroke in mice.","date":"2023","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/36793857","citation_count":25,"is_preprint":false},{"pmid":"19351798","id":"PMC_19351798","title":"NK1 receptor antagonism and emotional processing in healthy volunteers.","date":"2009","source":"Journal of psychopharmacology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/19351798","citation_count":25,"is_preprint":false},{"pmid":"21993526","id":"PMC_21993526","title":"A pharmacokinetic PET study of NK₁ receptor occupancy.","date":"2011","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/21993526","citation_count":24,"is_preprint":false},{"pmid":"15093555","id":"PMC_15093555","title":"The role of intrahepatic CD8+ T cell trapping and NK1.1+ cells in liver-mediated immune regulation.","date":"2004","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/15093555","citation_count":24,"is_preprint":false},{"pmid":"34709351","id":"PMC_34709351","title":"HVEM structures and mutants reveal distinct functions of binding to LIGHT and BTLA/CD160.","date":"2021","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34709351","citation_count":24,"is_preprint":false},{"pmid":"25179432","id":"PMC_25179432","title":"CD160 isoforms and regulation of CD4 and CD8 T-cell responses.","date":"2014","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25179432","citation_count":24,"is_preprint":false},{"pmid":"7694756","id":"PMC_7694756","title":"Identification of both NK1 and NK2 receptors in guinea-pig airways.","date":"1993","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/7694756","citation_count":24,"is_preprint":false},{"pmid":"11353005","id":"PMC_11353005","title":"Differential expression of functionally identified and immunohistochemically identified NK(1) receptors on sympathetic neurons.","date":"2001","source":"Journal of neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/11353005","citation_count":24,"is_preprint":false},{"pmid":"20430440","id":"PMC_20430440","title":"Immunolocalization of NK-1 receptor and Substance P in human normal placenta.","date":"2010","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/20430440","citation_count":23,"is_preprint":false},{"pmid":"9619484","id":"PMC_9619484","title":"Natural killer cell proliferation induced by anti-NK1.1 and IL-2.","date":"1998","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/9619484","citation_count":23,"is_preprint":false},{"pmid":"9030975","id":"PMC_9030975","title":"Functional characterization of NK1.1 + Ly-6C+ cells.","date":"1996","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/9030975","citation_count":23,"is_preprint":false},{"pmid":"27198610","id":"PMC_27198610","title":"α-Galactosylceramide-activated murine NK1.1(+) invariant-NKT cells in the myometrium induce miscarriages in mice.","date":"2016","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27198610","citation_count":23,"is_preprint":false},{"pmid":"16167886","id":"PMC_16167886","title":"Differentiation of NK1 and NK2 cells.","date":"2005","source":"Critical reviews in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16167886","citation_count":22,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47138,"output_tokens":5050,"usd":0.108582},"stage2":{"model":"claude-opus-4-6","input_tokens":8620,"output_tokens":3550,"usd":0.197775},"total_usd":0.306357,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"CD160 (BY55) was cloned and identified as a cysteine-rich, glycosylphosphatidylinositol (GPI)-anchored protein of 181 amino acids with a single Ig-like domain weakly homologous to killer inhibitory receptors; it forms tightly disulfide-linked multimers (~80 kDa unreduced, ~27 kDa reduced/carboxyamidomethylated) and is expressed on CD56dim CD16+ NK cells with high cytolytic activity but not on CD56bright CD16- NK cells.\",\n      \"method\": \"cDNA cloning, RNA blot analysis, immunoprecipitation with reduction and carboxyamidomethylation, flow cytometry\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original molecular cloning with biochemical characterization of multimer structure and isoform-specific expression\",\n      \"pmids\": [\"9743336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CD160 (BY55) acts as a co-receptor in TCR signal transduction: engagement of CD160 on CD28-negative CD8+ effector T cells enhances CD3-induced proliferation, and CD160 co-precipitates with the protein tyrosine kinase p56lck and tyrosine-phosphorylated zeta chains upon TCR-CD3 activation.\",\n      \"method\": \"Anti-CD160 mAb stimulation of primary T cells, proliferation assays, co-immunoprecipitation\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP of signaling molecules with functional proliferation readout, single lab\",\n      \"pmids\": [\"11978774\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CD160 expressed on circulating CD56dim NK cells mediates cytotoxic activity against K562 target cells via engagement of HLA-C molecules; direct interaction between recombinant soluble HLA-Cw3 and CD160 proteins was demonstrated, and CD158b inhibitory receptors partially interfered with CD160-mediated cytotoxicity.\",\n      \"method\": \"Functional cytotoxicity assays with anti-CD160 mAb blocking, binding assay with recombinant soluble proteins, flow cytometry\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct protein interaction demonstrated with recombinant proteins plus functional cytotoxicity assay; moderate evidence\",\n      \"pmids\": [\"12486241\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CD160-mediated NK cell effector functions (cytotoxicity and cytokine production including IFN-γ, TNF-α, and IL-6) require phosphatidylinositol 3-kinase (PI3K) recruitment: CD160 engagement induces polarization and co-localization with PI3K, phosphorylation of Akt, activation of the ERK downstream pathway, and involvement of upstream Syk kinase.\",\n      \"method\": \"Confocal microscopy, pharmacological PI3K/MEK/Syk inhibitors, western blotting for phospho-Akt/phospho-ERK/phospho-Syk, cytotoxicity and cytokine release assays\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (imaging, pharmacological inhibitors, western blot) in single lab establishing signaling cascade\",\n      \"pmids\": [\"17307798\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CD160 was identified as a ligand for HVEM (herpesvirus entry mediator) that delivers a coinhibitory signal; the cysteine-rich domain 1 (CRD1) of HVEM is essential for binding of CD160 (and BTLA) but not the costimulatory ligand LIGHT, and deletion or blockade of HVEM CRD1 abolishes CD160/BTLA binding and converts HVEM to a dominant costimulatory molecule.\",\n      \"method\": \"Binding assays, domain deletion/blockade experiments, functional T cell activation assays\",\n      \"journal\": \"Immunological reviews\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — domain-mapping with functional readout; review summarizing experimental data from primary studies\",\n      \"pmids\": [\"19426226\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"In CLL B cells (which aberrantly express CD160), CD160 signaling promotes survival by upregulating Bcl-2, Bcl-xL, and Mcl-1, reduces mitochondrial membrane potential collapse and cytochrome c release, induces DNA synthesis and proliferation, stimulates IL-6 and IL-8 secretion, and these effects are dose-dependently suppressed by PI3K inhibitors.\",\n      \"method\": \"CD160 stimulation of primary CLL cells, cell viability assays, western blotting for Bcl-2 family proteins, mitochondrial potential assays, cytochrome c release, BrdU proliferation, ELISA, PI3K inhibitor pharmacology\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods demonstrating PI3K-dependent survival signaling with mechanistic endpoints\",\n      \"pmids\": [\"20164468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CD160 is expressed on endothelial cells of newly formed blood vessels in human colon carcinoma and mouse melanoma but not in healthy tissue vessels; a monoclonal antibody (CL1-R2) targeting CD160 exerted antiangiogenic effects in multiple animal models (rabbit cornea FGF2-induced neovascularization, mouse oxygen-induced retinopathy, mouse Matrigel plug), and combined with chemotherapy caused regression and normalization of tumor vasculature.\",\n      \"method\": \"Immunohistochemistry, rabbit cornea assay, mouse oxygen-induced retinopathy, Matrigel plug assay, Doppler ultrasonography, intravital microscopy, histology\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple in vivo models with functional vascular readouts in a single study\",\n      \"pmids\": [\"21482699\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CD160 is a unique GPI-anchored activating NK receptor that signals through PI3K recruitment and lacks intrinsic ITAMs; it recognizes both MHC class Ia and Ib molecules and triggers cytotoxicity and proinflammatory cytokine production (IFN-γ, TNF-α, IL-6, IL-8, MIP1-β) at levels exceeding those induced by CD16 engagement.\",\n      \"method\": \"Functional NK cytotoxicity and cytokine release assays, specific antibody engagement, comparison with CD16-mediated responses\",\n      \"journal\": \"Immunology letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — review synthesizing multiple experimental findings from primary studies; GPI-anchor/ITAM-lacking characterization is structurally grounded\",\n      \"pmids\": [\"21324341\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Blocking the CD160–HVEM interaction with anti-HVEM antibody increased HIV-specific CD8 T cell proliferation and cytokine production, demonstrating that CD160 signals through HVEM to suppress T cell function; co-expression of CD160 and PD-1 on CD8 T cells defines a highly exhausted subset with downregulated NFκB signaling and upregulated inhibitors of T cell survival.\",\n      \"method\": \"HVEM blockade functional assay, flow cytometry, transcriptional profiling (microarray)\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ligand blockade functional rescue plus transcriptional mechanistic characterization; single lab\",\n      \"pmids\": [\"22916009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HVEM specifically activates CD160 on human CD56dim NK cells: HVEM engagement costimulated NK cells via CD160 (not BTLA), enhanced IFN-γ and TNF-α secretion induced by type I IFN and IL-2, and caused rapid hyperphosphorylation of ERK1/2 and AKT and enhanced cytolysis of target cells. In contrast, HVEM activation of BTLA reduced cytolysis.\",\n      \"method\": \"Human NK cell stimulation assays, selective receptor engagement with HVEM ligand, phosphoprotein western blotting (ERK1/2, AKT), cytotoxicity assays, cytokine ELISA\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — mechanistic signaling dissection (phosphoproteins) plus functional cytotoxicity and cytokine readouts; multiple orthogonal methods\",\n      \"pmids\": [\"23761635\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CD160 negatively regulates TCR-mediated signaling independently of PD-1: CD160+ CD8 T cells have reduced proliferation and perforin expression, and blockade of the CD160/CD160-ligand interaction restores proliferation in proportion to the ex vivo frequency of CD160+ cells. CD160 expression was not induced by T cell activation unlike PD-1.\",\n      \"method\": \"CD160 ligand blockade functional assay, flow cytometry, proliferation assays with virus-specific CD8 T cells (influenza, EBV, CMV antigens)\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional rescue by receptor blockade with multiple virus specificities; single lab\",\n      \"pmids\": [\"25255144\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CD160 exists in two isoforms (CD160-GPI and CD160-TM) both expressed in human primary CD4+ and CD8+ T cells; both isoforms bind HVEM, though CD160-TM binds less efficiently. HVEM antibodies blocked binding to CD160-GPI but paradoxically enhanced binding to CD160-TM, suggesting antibody-induced HVEM multimerization or conformational change. CD160-GPI triggering (via bead-bound HVEM-Fc or anti-CD160 mAb) enhanced Jurkat cell activation, consistent with a costimulatory role.\",\n      \"method\": \"Quantitative RT-PCR, flow cytometry, Time-Resolved Fluorescence binding assay, Jurkat cell activation assay\",\n      \"journal\": \"Journal of translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — isoform identification and binding characterization with functional cell activation assay; single lab\",\n      \"pmids\": [\"25179432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"A novel CD160+CD4+ T cell subset was identified in inflammatory skin lesions (atopic dermatitis, contact dermatitis, psoriasis); CD160 engagement acted as a co-activator receptor for CD3-induced proliferation in this subset. CD160 transcripts could be induced in IL-2 or IL-15-activated CD4+ peripheral blood lymphocytes.\",\n      \"method\": \"Immunohistochemistry of skin biopsies, RT-PCR, T cell proliferation assay with anti-CD160 co-stimulation\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — identification of new CD4+ subset with functional co-stimulation assay; single lab\",\n      \"pmids\": [\"17218942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structures of the human CD160 extracellular domain alone and in complex with HVEM were solved; CD160 adopts a unique variation of the immunoglobulin fold, exists as a monomer in solution, and the CD160:HVEM assembly exhibits 1:1 stoichiometry with a binding interface similar to that of the BTLA:HVEM complex.\",\n      \"method\": \"X-ray crystallography, solution biophysics\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure of CD160 alone and CD160:HVEM complex with 1:1 stoichiometry determination\",\n      \"pmids\": [\"31230945\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Crystal structures of HVEM-LIGHT-CD160 ternary complex demonstrated that HVEM can interact simultaneously with LIGHT (TNF ligand) and CD160 (Ig superfamily member) via distinct non-overlapping surfaces; HVEM mutants selectively recognizing either TNF or Ig ligands showed that LIGHT mediates bacterial clearance in the intestine while Ig ligands (including CD160) ameliorate liver inflammation in vivo.\",\n      \"method\": \"X-ray crystallography (ternary complex), site-directed mutagenesis, knockin mouse models with selective HVEM mutants\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — ternary complex crystal structure plus genetic knockin mice dissecting ligand-specific functions in vivo\",\n      \"pmids\": [\"34709351\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CD160 provides costimulatory signals to CD8+ T cells required for optimal clearance of oral Listeria monocytogenes infection: CD160-/- mice failed to clear infection efficiently, with reduced frequencies of granzyme B+ intraepithelial lymphocytes and granzyme B+, IFN-γ+TNF-α+ splenic CD8+ T cells. Adoptive transfer of CD160-/- CD8+ T cells into RAG-/- recipients caused higher mortality and bacterial burden than WT CD8+ T cells. NK cells did not contribute to impaired clearance.\",\n      \"method\": \"CD160 knockout mice, oral infection model, flow cytometry, adoptive transfer experiments, RAG-/- recipients\",\n      \"journal\": \"ImmunoHorizons\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with adoptive transfer epistasis; multiple orthogonal readouts\",\n      \"pmids\": [\"31022694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Reduced CD160 expression on intratumoral NK cells in HCC impairs IFN-γ production; TGFβ1 in the tumor microenvironment interferes with IFN-γ production by CD160+ NK cells, and TGFβ1 blockade specifically restores IFN-γ production by CD160+ NK cells. Transcriptomic analysis of sorted CD160+ vs CD160- NK cells confirmed functional activation signatures in CD160+ cells.\",\n      \"method\": \"Flow cytometry, transcriptomic microarray/gene set enrichment analysis of sorted NK cell subsets, TGFβ1 blockade functional assay, histology of patient tumors\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic TGFβ1 blockade experiment plus transcriptomics; single study with multiple orthogonal methods\",\n      \"pmids\": [\"30232222\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In patients with CLL, IL-16 in the plasma (highly elevated) directly upregulates CD160 expression on T cells, and extracellular vesicles (EVs) from CLL plasma serve as an additional source of CD160 that can be taken up by T cells, contributing to CD160-associated T cell exhaustion.\",\n      \"method\": \"Plasma cytokine profiling, EV characterization, in vitro IL-16 treatment of T cells, flow cytometry\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — in vitro upregulation experiment plus EV uptake; single lab study\",\n      \"pmids\": [\"33931471\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The BY55 (CD160) antigen (~80 kDa on the cell surface) marks cytotoxic lymphocytes; within cord blood, BY55+ cells correspond exclusively to a CD3- subset that contains the entire natural killer activity, demonstrating that CD160 expression is restricted to cytotoxic NK and T cell lineages.\",\n      \"method\": \"BY55 monoclonal antibody staining, flow cytometry, functional NK cytotoxicity assays on cord blood and bone marrow lymphocytes\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional NK activity directly linked to BY55+ subset by flow cytometry and cytotoxicity assays\",\n      \"pmids\": [\"8090781\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Murine CD160 is expressed predominantly on CD44high CD8+ memory T cells (both effector memory and central memory) and recently activated CD8+ T cells; CD160+ CD8+ T cells from OT-1 transgenic mice produce IFN-γ more rapidly than CD160- CD8+ T cells upon antigen stimulation, and soluble CD160 is released after in vitro CD3-mediated stimulation.\",\n      \"method\": \"Anti-murine CD160 mAb generation, flow cytometry, in vitro stimulation assays, intracellular IFN-γ staining\",\n      \"journal\": \"Immunology letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — first characterization of murine CD160 with functional antigen-specific T cell readout\",\n      \"pmids\": [\"16764942\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CD160 is a GPI-anchored (with an alternative transmembrane isoform) single-domain Ig superfamily receptor that, upon engagement of HLA class I molecules or HVEM (its principal signaling partner, revealed by 1:1 crystal structure), activates NK cells and CD8+ T cells via a PI3K→Akt/ERK signaling cascade (with upstream Syk involvement) to drive cytotoxicity and proinflammatory cytokine production (IFN-γ, TNF-α, IL-6, IL-8), while simultaneously delivering coinhibitory signals to exhausted CD8+ T cells that suppress TCR-driven proliferation; its function is context-dependent—costimulatory for NK cells and mucosal CD8+ T cells during infection, yet coinhibitory in chronic antigen settings—and is also expressed on tumor-associated endothelium where it supports pathological angiogenesis.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CD160 is a GPI-anchored, single Ig-domain receptor on cytotoxic lymphocytes and endothelial cells that delivers context-dependent activating or inhibitory signals through engagement of MHC class I molecules and HVEM. On NK cells and effector CD8+ T cells, CD160 ligation triggers a PI3K→Akt/ERK signaling cascade (with upstream Syk involvement) that drives cytotoxicity and proinflammatory cytokine production (IFN-γ, TNF-α, IL-6, IL-8), and CD160-deficient mice fail to clear mucosal Listeria infection due to impaired CD8+ T cell effector function [PMID:17307798, PMID:23761635, PMID:31022694]. Conversely, CD160 engagement via HVEM on chronically stimulated CD8+ T cells delivers a coinhibitory signal that suppresses TCR-driven proliferation independently of PD-1, defining CD160+PD-1+ cells as a deeply exhausted subset [PMID:22916009, PMID:25255144]. Structurally, CD160 binds HVEM CRD1 with 1:1 stoichiometry at a site overlapping the BTLA-binding surface but non-overlapping with LIGHT, and HVEM can simultaneously engage LIGHT and CD160 in a ternary complex that partitions distinct immunoregulatory outputs in vivo [PMID:31230945, PMID:34709351].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Establishing that CD160 (BY55) marks a cytotoxic lymphocyte lineage answered the basic question of which cells express this antigen, showing it defines the entire NK compartment in cord blood.\",\n      \"evidence\": \"Monoclonal antibody staining and functional NK cytotoxicity assays on cord blood and bone marrow lymphocytes\",\n      \"pmids\": [\"8090781\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No molecular identity or gene structure yet determined\", \"Expression on T cell subsets not fully mapped\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Molecular cloning of CD160 established its identity as a GPI-anchored, disulfide-linked multimeric Ig-superfamily receptor preferentially expressed on CD56dim CD16+ NK cells, providing the molecular framework for all subsequent functional studies.\",\n      \"evidence\": \"cDNA cloning, RNA blot analysis, immunoprecipitation under reducing/non-reducing conditions, flow cytometry\",\n      \"pmids\": [\"9743336\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligand identity unknown\", \"Signaling mechanism undefined\", \"Function beyond expression pattern not demonstrated\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Two contemporaneous studies revealed CD160's dual functionality: it directly binds HLA-C to trigger NK cytotoxicity and acts as a TCR co-receptor on CD28-negative CD8+ T cells by co-precipitating with p56lck and phospho-ζ chains, establishing CD160 as an activating receptor on both NK cells and T cells.\",\n      \"evidence\": \"Recombinant soluble protein binding assays, functional cytotoxicity assays, co-immunoprecipitation, T cell proliferation assays\",\n      \"pmids\": [\"12486241\", \"11978774\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling intermediates downstream of lck/ζ not mapped\", \"p56lck co-IP not validated reciprocally\", \"Whether CD160 inhibitory function exists not yet addressed\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Mapping the CD160 signaling cascade in NK cells resolved how a GPI-anchored receptor lacking ITAMs transduces activation signals: PI3K recruitment leads to Akt and ERK phosphorylation with upstream Syk kinase involvement, driving both cytotoxicity and cytokine secretion. Concurrently, CD160 was identified as a co-activator on a novel CD4+ T cell subset in inflammatory skin.\",\n      \"evidence\": \"Confocal microscopy, pharmacological PI3K/MEK/Syk inhibitors, western blotting, cytotoxicity and cytokine assays; immunohistochemistry of skin biopsies and T cell proliferation assays\",\n      \"pmids\": [\"17307798\", \"17218942\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Adaptor protein linking GPI-anchored CD160 to intracellular Syk/PI3K unknown\", \"Role of lipid raft partitioning not formally tested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identification of HVEM as a CD160 ligand and mapping the interaction to HVEM CRD1 reframed CD160 as part of a bidirectional HVEM signaling network, where CRD1 engagement by CD160/BTLA delivers coinhibitory signals while LIGHT engages distinct CRDs for costimulation.\",\n      \"evidence\": \"Binding assays, HVEM domain deletion/blockade, functional T cell activation assays\",\n      \"pmids\": [\"19426226\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Review-level summary; primary structural data for the CD160:HVEM interface not yet available\", \"Whether CD160 and BTLA compete for HVEM CRD1 or cooperate not resolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstration that CD160 signals in CLL B cells to upregulate Bcl-2/Bcl-xL/Mcl-1 via PI3K, promoting survival and cytokine secretion, expanded CD160's role beyond lymphocyte activation to a pro-survival pathway exploited in malignancy.\",\n      \"evidence\": \"CLL primary cell stimulation, viability and BrdU assays, western blotting for Bcl-2 family, mitochondrial potential assays, PI3K inhibitor pharmacology\",\n      \"pmids\": [\"20164468\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this represents aberrant expression or a normal B cell function is unclear\", \"Ligand triggering CD160 on CLL cells in vivo not identified\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Discovery of CD160 expression on tumor-associated endothelium and demonstration that anti-CD160 antibody CL1-R2 blocks pathological angiogenesis in multiple in vivo models revealed a non-immune function for CD160 in vascular biology.\",\n      \"evidence\": \"Immunohistochemistry, rabbit cornea neovascularization, mouse oxygen-induced retinopathy, Matrigel plug assay, Doppler ultrasonography\",\n      \"pmids\": [\"21482699\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endothelial CD160 signaling pathway not dissected\", \"Ligand for CD160 on endothelial cells not identified\", \"Whether angiogenic role is HVEM-dependent unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Blocking the CD160–HVEM axis on HIV-specific CD8+ T cells restored proliferation and cytokine production, directly demonstrating that CD160-HVEM engagement delivers a coinhibitory signal in chronic infection and that CD160+PD-1+ double-positive cells represent the most exhausted subset with downregulated NF-κB.\",\n      \"evidence\": \"Anti-HVEM antibody blockade, flow cytometry, microarray transcriptional profiling of HIV-specific CD8+ T cells\",\n      \"pmids\": [\"22916009\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Blockade targeted HVEM, not CD160 directly, so contributions of BTLA cannot be fully excluded\", \"NF-κB downregulation is correlative from transcriptomics\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Selective engagement experiments on human NK cells resolved the paradox of HVEM's dual signaling: HVEM activates CD160 (not BTLA) on CD56dim NK cells to costimulate IFN-γ/TNF-α and hyperphosphorylate ERK1/2 and AKT, while BTLA engagement is inhibitory—demonstrating that the same ligand elicits opposite outcomes through different receptors.\",\n      \"evidence\": \"Human NK cell stimulation with selective HVEM engagement, phosphoprotein western blotting, cytotoxicity and cytokine ELISA\",\n      \"pmids\": [\"23761635\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How cell-type context determines whether CD160 or BTLA dominates the response is unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Two advances clarified CD160's inhibitory T cell role and isoform biology: CD160 was shown to inhibit TCR signaling independently of PD-1 (blockade of CD160-ligand interaction restored proliferation proportional to CD160+ frequency), and a transmembrane isoform (CD160-TM) was identified that binds HVEM less efficiently than CD160-GPI, with HVEM antibodies paradoxically enhancing CD160-TM binding.\",\n      \"evidence\": \"CD160 ligand blockade in virus-specific CD8+ T cells; quantitative RT-PCR, time-resolved fluorescence binding, Jurkat activation assays\",\n      \"pmids\": [\"25255144\", \"25179432\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"CD160-TM signaling pathway not dissected\", \"Whether GPI and TM isoforms deliver opposing signals in the same cell unknown\", \"Functional significance of antibody-enhanced CD160-TM binding unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"In vivo genetic evidence from CD160-knockout mice demonstrated that CD160 is required for optimal CD8+ T cell effector function during mucosal Listeria infection, with adoptive transfer confirming a cell-intrinsic costimulatory role; separately, TGF-β1 in the HCC tumor microenvironment was shown to suppress IFN-γ production by CD160+ NK cells.\",\n      \"evidence\": \"CD160−/− mice with oral Listeria infection, adoptive transfer into RAG−/− recipients; flow cytometry and TGF-β1 blockade in HCC patient NK cells with transcriptomic validation\",\n      \"pmids\": [\"31022694\", \"30232222\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CD160 costimulation in vivo is HVEM-dependent or MHC-dependent not determined\", \"Mechanism by which TGF-β1 suppresses CD160+ NK cell function not elucidated\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Crystal structures of CD160 alone and in complex with HVEM established 1:1 stoichiometry and revealed a unique Ig fold variant, providing the atomic basis for the CD160-HVEM interaction and showing it overlaps the BTLA-binding interface on HVEM.\",\n      \"evidence\": \"X-ray crystallography, solution biophysics\",\n      \"pmids\": [\"31230945\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of CD160 bound to MHC class I\", \"GPI-anchor and membrane-proximal region not resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"The ternary HVEM-LIGHT-CD160 crystal structure demonstrated that HVEM simultaneously engages a TNF ligand and an Ig-domain receptor via non-overlapping surfaces, and genetic knockin mice showed these two binding modes partition distinct immunological functions (bacterial clearance vs. liver inflammation control) in vivo. Separately, IL-16 and CLL-derived extracellular vesicles were shown to upregulate CD160 on T cells, linking the tumor microenvironment to CD160-mediated exhaustion.\",\n      \"evidence\": \"X-ray crystallography of ternary complex, HVEM mutant knockin mice; CLL plasma cytokine profiling, EV characterization, in vitro IL-16 treatment\",\n      \"pmids\": [\"34709351\", \"33931471\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ternary complex formation affects downstream signaling output quantitatively is unknown\", \"Whether EV-transferred CD160 is functional on recipient T cells not formally demonstrated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The molecular mechanism by which a GPI-anchored receptor (lacking intracellular domains) activates Syk and PI3K remains unresolved—the putative transmembrane adaptor or lipid-raft partner that couples CD160-GPI to intracellular kinases has not been identified.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No adaptor protein linking GPI-anchored CD160 to cytoplasmic signaling identified\", \"Relative physiological contributions of CD160-GPI vs CD160-TM isoforms undefined\", \"Structural basis of CD160 recognition of MHC class I molecules unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [2, 4, 9, 13]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [8, 10, 15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 11, 18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 3, 8, 9, 10, 15]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 5, 9]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"TNFRSF14\",\n      \"TNFSF14\",\n      \"BTLA\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}